Cost-effectiveness of organ donation: Evaluating investment into donor action and other donor initiatives

被引:80
作者
Whiting, JF [1 ]
Kiberd, B
Kalo, Z
Keown, P
Roels, L
Kjerulf, M
机构
[1] Maine Med Ctr, Portland, ME 04102 USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] Novartis AG, Basel, Switzerland
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[5] Donor Act Fdn, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
关键词
cost-effectiveness; organ donor; renal transplantation;
D O I
10.1111/j.1600-6143.2004.00373.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Initiatives aimed at increasing organ donation can be considered health care interventions, and will compete with other health care interventions for limited resources. We have developed a model capable of calculating the cost-utility of organ donor initiatives and applied it to Donor Action, a successful international program designed to optimize donor practices. The perspective of the payer in the Canadian health care system was chosen. A Markov model was developed to estimate the net present value incremental lifetime direct medical costs and quality adjusted life years (QALYs) as a consequence of increased kidney transplantation rates. Cost-saving and cost-effectiveness thresholds were calculated. The effects of changing the success rate and time frame of the intervention was examined as a sensitivity analysis. Transplantation results in a gain of 1.99 QALYs and a cost savings of Can$104000 over the 20-year time frame compared with waiting on dialysis. Implementation of an intervention such as Donor Action, which produced as few as three extra donors per million population, would be cost-effective at a cost of Can$ 1.0 million per million population. The cost-effectiveness of Donor Action and other organ donor initiatives compare favorably to other health care interventions. Organ donation may be underfunded in North America.
引用
收藏
页码:569 / 573
页数:5
相关论文
共 29 条
[1]   An economic evaluation of lung transplantation [J].
Anyanwu, AC ;
McGuire, A ;
Rogers, CA ;
Murday, AJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (03) :411-420
[2]  
BAXTER D, 2001, COMP CANADAS ORGAN D
[3]   A CONVENIENT APPROXIMATION OF LIFE EXPECTANCY (THE DEALE) .1. VALIDATION OF THE METHOD [J].
BECK, JR ;
KASSIRER, JP ;
PAUKER, SG .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) :883-888
[4]   Decision analysis models: Opening the black box [J].
Birkmeyer, JD ;
Liu, JY .
SURGERY, 2003, 133 (01) :1-4
[5]  
BOSCH X, 1999, J AM MED ASS, V282
[6]  
*CAN I HLTH INF, 2001, CAN ORG REPL REG 200, V2
[7]  
*CAN I HLTH INF, 2001, CAN ORG REPL REG, V1
[8]   Cyclosporin microemulsion (Neoral®) -: A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation [J].
Coukell, AJ ;
Plosker, GL .
PHARMACOECONOMICS, 1998, 14 (06) :691-708
[9]   Economic evaluation of end stage renal disease treatment [J].
de Wit, GA ;
Ramsteijn, PG ;
de Charro, FT .
HEALTH POLICY, 1998, 44 (03) :215-232
[10]  
EGGERS P, 1992, SEMIN NEPHROL, V12, P284